Print this page    •   Back to Web version of article

The Body Covers: The XIII International AIDS Conference

Sustained Virologic Suppression in Subjects Switched from Protease Inhibitors to Nevirapine

Coverage provided by Pablo Tebas, M.D.

July 12, 2000

One of the concerns about switching from protease inhibitors to NNRTIs has been that, by doing so, we would sacrifice some of the potency of the antiretroviral regimens and that patients would develop virologic failure. There is a growing body of evidence that tells us that is not the case. In this poster, Cotton (who works for Boehringer Ingelheim) reviewed eleven studies published or presented at international meetings in 1998 and 1999 that reported PI replacement with NVP (NRTIs were also changed in some cases).

A total of 370 HIV-suppressed patients who switched therapy were identified. In an on-treatment analysis at three and six months 281/303 (93%) and 176/204 (86%) patients respectively had maintained undetectable viral loads. The entry criteria was not the same in all studies, and some included patients with multi-nucleoside experience, so results are not directly comparable to other studies presented in this and other meetings in a more controlled population. In general, nevirapine is very well tolerated except for patients who develop a rash -- which in this composite analysis, had a frequency of only 4%. During this meeting we also learned that prednisone does not prevent rashes associated with nevirapine (see poster WePpB1378). Metabolic parameters improve quickly after the switch, and although a head-to-head comparison has not been performed with efavirenz, nevirapine seems to be more "lipid-friendly." The practical implication of this and other switch presentations is that our fears about lack of potency of some NNRTI-based regimens are not justified.

This article was provided by Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.